new tools and products for cancer research, diagnosis … · ~20% de la facturación de 2008....

Madrid, 29 de Madrid, 29 de SeptiembreSeptiembre de 2009de 2009

www.proteinalternatives.com

“New tools and products for cancer research, diagnosis and treatment”

““New tools and products for cancer research, diagnosis and treatment”

About Protein Alternatives SLAbout Protein Alternatives SL

PROALT is a biotech young company founded in 2006

It is located in Tres Cantos within the Bioincubator of Madrid´s Scientific Park.

Our focus is the use of recombinant proteins and antibodies for new cancer markers development and its application in other pathologies

Our strength is the strong knowledge on the cancer biomarkers field

We provide innovative technologies for production and purification of “rare or difficult to obtain” proteins and the generation of its respective antibodies.

M2

16

28

52

0 20 40 60

jun-07

ene-07

jul-06

m2

New tools and products for cancer research, diagnosis and treatment

R&D Director Researchers (3)Lab Technicians (2)

Juan Ignacio Imbaud, PhD. (Lab Director)Martín Pou Romay (CEO)Soledad Hernández (CFO)

Susana Rodríguez

Ignacio Casal Álvarez, PhD CIB-CSIC Staff Scientists (2008-)

Jorge Luis Martínez Torrecuadrada, PhDCNIO´s Biotech Programme researcher (2002-)

R&D TeamR&D Team

Management Management TeamTeam

Founders and Founders and Scientific AdvisorsScientific Advisors

Sales & MarketingSales & Marketing

Company's professionalsCompany's professionals

EQUIPO DE TRABAJO

76

54

32

810

11

0 2 4 6 8 10 12

ene-09

may-08

sep-07

sep-06

may-06

Nº de personas

““Adaptabilidad permanente Adaptabilidad permanente de las instalacionesde las instalaciones””

Personal altamente cualificadoPersonal altamente cualificado(% elevado de Doctores)(% elevado de Doctores)


Cancer biomarkers

-New products and reactives for research. -Partnering with R&D Centres-Wide collection of proteins and antibodies for R&D labs.

Tailored research services.

-Recombinant proteins production. (E coli, Baculovirus, Mammalian)

- Recombinant antibodies (scFvs).- Policlonal antibodies.

Individual projects and under cooperation

- New products (proteins and/or antibodies.- Diagnostic kits for cancer

Project - Recombinant antibodies against colorectal cancer.

PRODUCTS SERVICES R&D Projects

DIAGNOSTIC / PROGNOSTIC / CANCER THERAPY

Our competitivity is based on our know-how and the application of state-of-the-art technologies

Research Projects, Products and Services Research Projects, Products and Services

Our aim is to offer quality reagents (proteins/antibodies) for the new genomic and proteomic targets arising from the–omics technologies:

Construction of a recombinant protein collection ( 100% in 2009)

Identification and commercialization of tumoral biomarkers

- several novel cancer biomarkers (original and “rare” proteins) are investigated, which could be of interest because their potential application as early biomarkers.

- these clinically untested proteins constitute powerful tools for diagnostic, prognostic and/or therapeutic treatment of human diseases like cancer, diabetes, cardiovascular pathologies and other disorders (annexins, cytokines, interleukins and others).

- construction of protein microarrays.

Polyclonal and/or monoclonal antibody generation

- several organisms: rabbit, mouse, chicken.


About PROALT ProductsAbout PROALT Products~20% de la facturación de 2008

PROALT also offer custom-made integral services, performedunder individual customer contracts, in areas like:

Recombinant protein expression (From different organisms: Homo sapiens, Mouse, Xenopus, etc. in prokaryotic or eukaryotic systems: Escherichia coli, baculovirus and mammalian cells).

Recombinant protein purification (several tags: His6, MBP, GST or others).

Antibody generation: Polyclonal (pAb) and/or Monoclonal (mAb).

Developing new diagnostic biomarkers for cancer and other pathologies

Design and development of novel diagnostic kits (ELISA or Arrays) for proteins of interest.

Other specialized services in antibody technology such as ScFv / Fab Production, Construction of Murine and Human Phage Antibody Library, Antibody Humanization, among others.


About PROALT Custom ServicesAbout PROALT Custom Services


Main customersMain customers

Servicios finalizados: 20Servicios en curso: 5Servicios vendidos para 2009: 3-4 a gran escala

~80% de la facturación de 2008

Current CCR diagnosisCurrent CCR diagnosisBlood in feces, rectum, colonoscopy (invasive techniques)

Radiological studies, MRI, Computed Axial Tomography.

Biopsies results: weeks (ocular examination of tissue samples)

Consequences: there are metastasis in 15-20% of diagnosed cases.

Proposed solutions and advantages.Proposed solutions and advantages.Identify the best CCR markers (blood analysis; PSA prostatic analogues)

Design of a diagnosis [1] non invasive, [2] fast, [3]cheap, [4] simple and short (routine)

Supply the demand of reliable markers that currently exists.

OverviewOverviewCancer: first death cause in developed countries

CCR: 3rd in men (after lung and prostate gland) and 2nd in women

(after breast cancer) with 25.600 new cases every year in Spain.

CCR incidence: increasing ( 2,6% per year) due to population aging

Keys: early diagnosis.

R&D Projects in Colorectal cancer (CCR)R&D Projects in Colorectal cancer (CCR)

Diagnostic projects&

Therapeutic projects

U.S.A

Japón

Europa


Página Web PROALT

Clientes

Departamento de Ventas

- Instituciones Académicas- Grupos de Investigación- Universidades- Hospitales- Empresas farmacéuticas- Empresas biotecnológicas

Ventas y Marketing: red actual de comercializaciVentas y Marketing: red actual de comercializacióónn

- Personal Técnico-comercial

Courier

acuerdos firmados acuerdos en curso

China

http://www.nipponexpress.net/index2.htm

FinanciaciFinanciacióónn

Programa / Ayuda Duración ModalidadPrograma Torres Quevedo MEC 3 años Subvención

Ayudas Biotecnología 2007/08 y 2008/09 (Comunidad de Madrid) 3 años Subvención

PROFIT MITYC 2007 2 años Subvención

Orden de Parques 2007 2 años Préstamo reembolsable

Fundación Genoma España 2 años ---

Otras ayudas (ayudas Madri+d valoración, bolsas de viajes, etc) anuales Subvención

Fondos propios:Fondos propios:

Ayudas: prAyudas: prééstamos reembolsables y subvenciones:stamos reembolsables y subvenciones:

Otras herramientas financieras disponibles:Otras herramientas financieras disponibles:

CrCrééditos CDTIditos CDTI

Inversores Privados e Institucionales Inversores Privados e Institucionales (Capital Riesgo, (Capital Riesgo, BusinessBusiness AngelsAngels, , etcetc))

Subvenciones45%

Genoma España25%

Préstamos30%

Bioincubadora: FASE I Bioincubadora: FASE I de las empresas / Beneficios de las empresas / Beneficios


Disminución de las inversiones iniciales

Entorno proclive a la innovación y la investigación

Potenciación de sinergias

Ubicación e imagen: infraestructuras de calidad

Acceso a programas o ayudas específicos de Parques (créditos blandos)

Asesoramiento empresarial especializado

Aprovechamiento del marco relacional del Parque o Centro Tecnológico en el cual se alojan

““Incremento de la tasa de Incremento de la tasa de ééxito de los emprendimientosxito de los emprendimientos””

InstalacionesInstalaciones

NecesidadesNecesidades

FuturoFuturo de PROALT: FASE II de de PROALT: FASE II de AceleraciAceleracióónn

Problemática actual: existen pocos espacios a nivel nacional que concentren empresas en esta Fase II de desarrollo (cooperación e imagen)

Fase I: Bio-incubadora proceso de crecimiento y maduración

Fase II: Aceleradora Imprescindible la reubicación en un entorno estable a largo plazo

Laboratorios para empresas (300-400 m2)

Zonas comunes

Servicios comunes (pocos)

Recursos Humanos

Contratación de un Gerente

Personal auxiliar administrativo

Responsable infraestructuras


PROALT is a tech-based company that utilizes the most recent technologies in biomarkers field. We develop our own R&D-based products.

Our objective is to become leaders in the development of new diagnostic products in cancer.

We have an experimented and multidisciplinary promoter and scientific team.

PROALT targets the opportunity and has a great growth potential.

Our aim is to continue and promote the internationalization plan with high-quality products and services.

We promote collaboration with academic institutions, Hospitals, Universities, and other Pharma or Biotech companies for tech transfer and the development of innovative and co-operative projects.

SummarySummary

Protein Alternatives SLProtein Alternatives SL


C/ Santiago Grisolía, 2PTM – Parque Científico de Madrid

28760 Tres Cantos. MADRIDPhone / Fax: 91 804 79 74

Juan Ignacio ImbaudHead of Laboratory

[email protected]

www.proteinalternatives.comwww.proteinalternatives.com

new tools and products for cancer research, diagnosis … · ~20% de la facturación de 2008....

Documents